1 / 52

AN ORAL HISTORY OF LYNCH SYNDROME, FAP, AND HEREDITARY DIFFUSE GASTRIC CANCER by

AN ORAL HISTORY OF LYNCH SYNDROME, FAP, AND HEREDITARY DIFFUSE GASTRIC CANCER by HENRY T. LYNCH, M.D. JANE F. LYNCH, B.S.N. Creighton University School of Medicine Omaha, Nebraska. Magnitude of the Problem. Annual worldwide incidence of CRC is 1,023,152*:

bridie
Download Presentation

AN ORAL HISTORY OF LYNCH SYNDROME, FAP, AND HEREDITARY DIFFUSE GASTRIC CANCER by

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AN ORAL HISTORY OF LYNCH SYNDROME, FAP, AND HEREDITARY DIFFUSE GASTRIC CANCER by HENRY T. LYNCH, M.D. JANE F. LYNCH, B.S.N. Creighton University School of Medicine Omaha, Nebraska

  2. Magnitude of the Problem • Annual worldwide incidence of CRC is 1,023,152*: • • Lynch syndrome (LS) accounts for  2-5% • (20,460-51,160 cases). • • < 1% (10,230 cases) constitute FAP. • •  20% (204,630 cases) are familial (2 or more first- • degree relatives with CRC. • • Each family is a cancer prevention target! • *International Agency for Research on Cancer. Globocan 2002. Available at: http://www-dep.iarc.fr/.

  3. Family History, Cancer Risk,and Diagnosis

  4. History of Hereditary Cancer • History of FAP: • Historical review detailed by Bussey*. • Menzelio** (1721) - first example of patient with large number of polyps in GI tract. • Cripps*** (1882) reported polyposis in 2 members of same family; likely first indication that it was familial. • *Familial Adenomatous Polyposis. New York: Alan R. Liss Inc., 1990, pp. 1-7. • **Ast Med Berolinensium 4:68-71, 1721. • ***Trans Pathol Soc London 33:165-168, 1882.

  5. History of Hereditary Cancer • History of FAP (continued): • Bickersteth* (1890) reported a family with affected members in 2 generations (mother and son). • Smith** (1887) “adenocarcinoma” of colon in 3 members of a family with multiple polyps. • *Hosp Rep 26:299-301, 1890. • **St Bartholomew’s Hos Rep 23:225-229, 1887.

  6. History of Hereditary Cancer • St. Mark’s Hospital and Cancer Registry: • Cuthbert Dukes, consultant pathologist at St. Mark’s, pioneered family studies, importance of pedigree. • FAP Registry at St. Mark’s established 1925. • Polyp registry for all varieties of polyposis syndromes.

  7. Associated Extracolonic Lesions • Gardner and Richards (1953) published a polyposis family with the following: • • multiple osteomas of the cranium and mandible; • • multiple epidermoid cysts; • • fibromas of the skin; • Subsequently called Gardner’s syndrome. • Additional findings in same family: • • dental abnormalities (supernumerary teeth); • • desmoid tumors of the abdominal wall; • • extension of osteomas to any part of skeletal system. • *Am J Hum Genet 5:139-147.

  8. Associated Extracolonic Lesions • Also associated with FAP: • • congenital hypertrophy of the retinal pigment • epithelium (CHRPE); • • gastric polyps (adenomas and fundic gland polyps); • • extracolonic carcinomas: • • stomach, • • duodenum, • • jejunum, • • pancreas, • • bile duct, • • papillary thyroid carcinoma, • • hepatoblastoma.

  9. History of FAP • Chromosome 5 and APC mutation: • Herrera et al* (1986) identified interstitial deletion of chromosome 5 in patient with multiple developmental abnormalities and colonic polyps. • Bodmer et al** (1987) gave evidence for APC mutation on chromosome 5. • *Am J Med Genet 25:473-476. • **Nature 328:614-616.

  10. History of FAP • Attenuated FAP: • Lynch et al* (1988) reported a cancer-prone family with a few adenomas, autosomal dominant, described initially as hereditary flat adenoma syndrome. • Spirio et al. (1992**- 1993***) linked this family and others with similar phenotypes to chromosome 5q (APC locus). • *J Natl Cancer Inst 80:278-282. • **Am J Hum Genet 51:92-100. • ***Cell 75:951-957.

  11. Attenuated FAP • Later onset (CRC ~age 50) • Few colonic adenomas • Not associated with CHRPE • UGI lesions • Associated with mutations at extreme 5’, 3' ends of APC gene, & exon 9A

  12. Gastric Cancer

  13. Associated Extracolonic Lesions • Desmoids • Difficult and dangerous to manage. • While not cancer, they extend and obstruct vital anatomic structures. • Surgery may provoke desmoid formation*. • *Lynch & Fitzgibbons. Am J Gastroenterol 91:2598- • 2601, 1996.

  14. History of Hereditary Cancer • Unacceptable mortality in FAP: • Arvanitis et al. at Cleveland Clinic showed that 59% of patients with FAP in 1990 were dying of metastatic CRC.* • Employment of FAP Registries** is helping to reduce mortality! • *Dis Colon Rectum 33:639-642, 1990. • **Int J Clin Oncol 9:308-316, 2004.

  15. The Danish Polyposis Registry* • ProbandsCall-up ptsp • CRC dx 170/252 (67%) 5/182 (3%) < 0.001 • CCS1 44% 94% < 0.0001 • ___________________________________________________________________ • <19751976-2001p • CRC prevalence 60% 27% < 0.0001 • colectomy use 52% 93% < 0.00001 •  CCS1 in FAP with time: < 0.00001 • Conclusion: Registry participation likely main cause of  in CCS1. • 1CCS = cumulative crude survival • *Bülow. Gut 52:742-746, 2003.

  16. Dr. Aldred Scott WARTHIN (1866-1931)

  17. Aldred Scott Warthin, M.D., Ph.D.(1866-1931) A distinguished portion of his achievement centers on the relationship between cancer and genetics, which predated the rediscovery of Mendel’s principles and opened the question of cancer-prone families for modern study. He can properly be called “The Father of Cancer Genetics.”

  18. Archives of Internal Medicine Vol. 12, July-Dec., 1913

  19. Archives of Internal Medicine Vol. 12, July-Dec., 1913

  20. LYNCH SYNDROME

  21. Archives of Internal Medicine Vol. 117, Feb., 1966.

  22. JAMA 294:2195-2202, 2005.

  23. Could this be hereditary Colon Cancer

  24. First Lynch Syndrome Family in South America, published by my colleagueCarlos Sarroca* • Cancer colonico familiar sin poliposis: enfoque clinico y anatomopatologico. Perspectivas de estudio genetico. • C. Sarroca, WA. Ferreira, R. Quadrelli • Cir del Uruguay 47:515-520, 1977.

  25. Arch Intern Med 141:607-611, 1981

  26. Science 260:810-812, 1993.

  27. Genetic Heterogeneity in HNPCC MSH6 MLH1 MSH2 PMS2 PMS1 Chr 7 Chr 3 Chr 2 HNPCC is associated with germline mutations in any one of at least five genes

  28. Lynch Syndrome: Genotypic Heterogeneity Clinical cancer phenotypes differ with each of the MMR mutations: 1. MSH2 has  extracolonic cancer types and  Muir-Torre syndrome 2. MLH1 may have  CRC expression. 3. MSH6 may be more “benign” with  CRC but  endometrial cancer.

  29. Cardinal Features of Lynch Syndrome • • Family pedigree shows autosomal dominant inheritance pattern for syndrome • cancers. • • Earlier average age of CRC onset than in the general population: • - Lynch syndrome: 45 years; • - general population: 63 years. • • Accelerated carcinogenesis, i.e., shorter time for a tiny adenoma to develop into • a carcinoma: • - Lynch syndrome: 2-3 years; • - general population: 8-10 years. • High risk of additional CRCs: 25-30% of patients who have surgery for a LS-associated CRC will have a second primary CRC within 10 years, if surgery was < a subtotal colectomy. • • Increased risk for certain extracolonic malignancies: • - endometrium (40-60% lifetime risk for ♀ carriers); • - ovary (12% lifetime risk for ♀ carriers); • - stomach (higher risk in families from Orient); • - small bowel;

  30. Cardinal Features of Lynch Syndrome • • Increased risk for certain extracolonic malignancies (continued): • - hepatobiliary tract; • - pancreas; • - upper uroepithelial tract (transitional cell carcinoma of the ureter and renal • pelvis); • - brain (in Turcot’s syndrome variant of LS); • - sebaceous adenomas, sebaceous carcinomas, multiple keratoacanthomas • (in Muir-Torre syndrome variant of LS). • Differentiating pathology features of LS CRCs: • - more often poorly differentiated; • - excess of mucoid and signet-cell features; • - Crohn’s-like reaction; • - significant excess of infiltrating lymphocytes within the tumor. • • Increased survival from CRC. • • Sine qua non for diagnosis is identification of germline mutation in MMR gene (most • commonly MLH1, MSH2, MSH6) segregating in the family.

  31. Algorithm for Population Screening Colorectal Cancer + Family History STOP (sporadic) ­ IHC + for MLH1 + for MSH2 or MSH6 Sequencing (directed by IHC) ± MLPA (sequential or concurrent?) Hypermethylation, BRAF (V600E) ­ mutation + mutation - + STOP (Lynch) conversion; other tumor testing if available STOP (sporadic)

  32. Algorithm for Moderate/High Risk Patients (Moderate=Bethesda; High=Amsterdam II) Colorectal Cancer + Family History, Age < 50, etc. Syndrome X ??? STOP (sporadic) ­ MSI/IHC + for MLH1 + for MSH2 or MSH6 Sequencing (directed by IHC) ± MLPA (sequential or concurrent?) Hypermethylation, BRAF (V600E) ­ mutation + mutation - + Stop or Test blood for germline methylation ??? STOP (Lynch) Conversion; Or Linkage, Or Testing of other tumor if available - + STOP (other) STOP (Lynch)

  33. HEREDITARY GASTRIC CANCER

  34. Historical

  35. Suspected stomach cancer d. age at death Stomach cancer - macroscopic diagnosis at autopsy or per physician report Napoleon Bonaparte

  36. Familial Gastric Cancer: Lynch Syndrome • GC incidence shows large geographic differences worldwide in Lynch syndrome. • Lowest rates in most Western industrialized countries. • Relatively high rates of GC occur in Lynch syndrome in Japan, Korea, China, and South America (particularly Chile).

  37. Familial Gastric Cancer • Intestinal type: • More common in general population; • More likely to be sporadic and related to environmental factors such as diet, particularly salted fish and meat, smoked foods, cigarette smoking, and alcohol use; • Pathology - Components of glandular, solid, or intestinal architecture, as well as tubular structures; • H. pylori infection a risk for intestinal type with lesser involvement in diffuse type.

  38. Hereditary Gastric Cancer • Intestinal type has shown a worldwide decline in incidence; DGC remains stable and may even be increasing. • Diffuse gastric cancer (DGC) is more often described etiologically with host factor effects. • *Lynch et al. J Surg Oncol 90:114-133, 2005. • **Crew & Neugut. World J Gastroenterol12: 354-362, 2006.

  39. 5-10% of gastric cancer is familial, and between 1-3% is hereditary.* • Historically, Guilford et al.*** described the truncating CDH1 • germline mutations accounting for HDGC in 3 Maori families, • showing autosomal dominant inheritance of this disease. • It is estimated that  30-40% of HDGC families harbor • E-cadherin (CDH1) germline mutations.** • *Lynch et al. J Surg Oncol 90:114-133, 2005. • **Caldas et al. J Med Genet 36:873-880, 1999. • ***Nature 392:402-405, 1998. Hereditary Diffuse Gastric Cancer (HDGC)

  40. Hereditary Diffuse Gastric Cancer (HDGC) • Hereditary diffuse gastric cancer (HDGC) first reported in 1964*. • In this original Maori kindred, a descendant died at age 14 and > 25 of his relatives have died of cancer**. • Guilford et al. first described E-cadherin (CDH1) germline mutations in HDGC in 1998**. • *Jones. N Z Med J 63:287-296, 1964. • **Guilford et al. Nature 392:402-405, 1998.

  41. Familial Gastric Cancer • Diffuse type: • More likely primary genetic etiology; • A subset (HDGC) due to E-cadherin (CDH1) germline mutation; • Pathology - poorly cohesive clusters, signet cells which infiltrate the gastric wall, widespread thickening and rigidity (linitus plastica); • Differential diagnosis, as in most hereditary forms of cancer, shows significant heterogeneity.

  42. CDH1 Mutations and HDGC • This knowledge has impacted heavily upon the care of HDGC families. • Surveillance has not been effective. • Prophylactic total gastrectomy has lifesaving potential*. • *Lewis et al. Surgery 130:612-619, 2001.

  43. Diffuse Gastric Cancer E-Cadherin Mutation Carriers Negative for E-Cadherin Mutation Prophylactic Gastrectomy Microscopic Foci of Early Diffuse Gastric Cancer

  44. Diffuse Gastric Cancer E-Cadherin Mutation Carriers Negative for E-Cadherin Mutation Prophylactic Gastrectomy Microscopic Foci of Early Diffuse Gastric Cancer

More Related